Recent advances in CAR T-cell engineering using synthetic biology: Paving the way for next-generation cancer treatment.


Journal

Advances in protein chemistry and structural biology
ISSN: 1876-1631
Titre abrégé: Adv Protein Chem Struct Biol
Pays: Netherlands
ID NLM: 101497281

Informations de publication

Date de publication:
2024
Historique:
medline: 19 5 2024
pubmed: 19 5 2024
entrez: 18 5 2024
Statut: ppublish

Résumé

This book chapter highlights a comprehensive exploration of the transformative innovations in the field of cancer immunotherapy. CAR (Chimeric Antigen Receptor) T-cell therapy represents a groundbreaking approach to treat cancer by reprogramming a patient immune cells to recognize and destroy cancer cells. This chapter underscores the critical role of synthetic biology in enhancing the safety and effectiveness of CAR T-cell therapies. It begins by emphasizing the growing importance of personalized medicine in cancer treatment, emphasizing the shift from one-size-fits-all approaches to patient-specific solutions. Synthetic biology, a multidisciplinary field, has been instrumental in customizing CAR T-cell therapies, allowing for fine-tuned precision and minimizing unwanted side effects. The chapter highlights recent advances in gene editing, synthetic gene circuits, and molecular engineering, showcasing how these technologies are optimizing CAR T-cell function. In summary, this book chapter sheds light on the remarkable progress made in the development of CAR T-cell therapies using synthetic biology, providing hope for cancer patients and hinting at a future where highly personalized and effective cancer treatments are the norm.

Identifiants

pubmed: 38762281
pii: S1876-1623(24)00012-9
doi: 10.1016/bs.apcsb.2024.02.003
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

91-156

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Sangita Dey (S)

CSO Department, Cellworks Research India Pvt Ltd, Bengaluru, Karnataka, India.

Moodu Devender (M)

Department of Animal Biology, School of Life Sciences, University of Hyderabad, Hyderabad, India.

Swati Rani (S)

ICAR, National Institute of Veterinary Epidemiology and Disease Informatics, Bengaluru, Karnataka, India.

Rajan Kumar Pandey (RK)

Department of Medical Biochemistry and Biophysics, Karolinska Institute, Solna, Sweden. Electronic address: rajan.kumar.pandey@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH